1. Home
  2. NVNI vs SNTI Comparison

NVNI vs SNTI Comparison

Compare NVNI & SNTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nvni Group Limited

NVNI

Nvni Group Limited

N/A

Current Price

$1.33

Market Cap

15.4M

Sector

N/A

ML Signal

N/A

Logo Senti Biosciences Inc.

SNTI

Senti Biosciences Inc.

N/A

Current Price

$1.00

Market Cap

22.8M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
NVNI
SNTI
Founded
2019
2016
Country
Brazil
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
15.4M
22.8M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
NVNI
SNTI
Price
$1.33
$1.00
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$9.00
AVG Volume (30 Days)
89.2K
116.7K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$6.67
N/A
Revenue Next Year
$26.67
$150.00
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.14
$0.80
52 Week High
$4.94
$5.10

Technical Indicators

Market Signals
Indicator
NVNI
SNTI
Relative Strength Index (RSI) 37.16 55.46
Support Level $1.10 $0.80
Resistance Level $1.64 $1.02
Average True Range (ATR) 0.15 0.06
MACD 0.04 0.02
Stochastic Oscillator 35.99 97.14

Price Performance

Historical Comparison
NVNI
SNTI

About NVNI Nvni Group Limited

Nvni Group Ltd is a holding company that conducts all of its business through Nuvini SA and Nuvini acquired companies. Nuvini S.A. acquires and operates software companies within SaaS markets in Brazil. Nuvini S.A. is the private serial software business acquirer in Brazil and intends to use funding and capital markets access to continue expanding its acquisition plans in Brazil and Latin America. The Company has determined that it has a single operating and reportable segment which is multi-vertical SaaS solution model.

About SNTI Senti Biosciences Inc.

Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.

Share on Social Networks: